AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05750212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tenderness
Description: Tenderness is a binary measurement of the pelvic floor muscle on physical examination
Study NCT05750212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Contraction
Description: Contraction is a binary measurement of the pelvic floor muscle on physical examination
Study NCT05750212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Relaxation
Description: Relaxation is a binary measurement of the pelvic floor muscle on physical examination
Study NCT05750212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: Electromyography is a measurement of the pelvic floor muscle in microvolts
Study NCT05750212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transperineal
Description: Transperineal measurements (in millimeters) of the pelvic floor muscle using an ultrasound
Study NCT05750212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pressure
Description: Pressure measurements (in millimeters) of the pelvic floor muscle using an algometer
Study NCT05831501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans abdominis plane block
Description: Ultrasound guided infiltration of local anaesthetic bupivacaine via 22G Quincke needle between internal oblique and trans abdominis muscle layers in abdominal wall.
Study NCT04659954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application O'DIDE
Description: The intervention is the use of an application that aimed to favorize contact between the patient and the care team between the consultations.
Study NCT05747326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral vinorelbine and capecitabine
Description: The eligible patients were enrolled to receive oral metronomic vinorelbine 40 mg on day 1, day 3, day 5 every week (Monday, Wednesday, and Friday) and capecitabine 500mg three times daily (tid) after meals every 3 weeks. Until disease progression or unacceptable toxicity occurred, or the patient refused medication, vinorelbine and capecitabine were administered continuously without drug-free periods over 21-day cycles.
Study NCT05717296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anxiety survey
Description: surgery and anesthesia anxiety questionnaire
Study NCT05717296 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: anxiety survey
Description: surgery and anesthesia anxiety questionnaire
Study NCT05717296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scale of satisfaction
Description: scale of satisfaction of multimedia
Study NCT05717296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia Information
Description: Patients randomized to the with multimedia support arm will have access to educational videos focused on the vascular surgery they are to receive.
Study NCT05697172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-intensity focused ultrasound
Description: 80-second stimulus with an estimated tissue ISSPA=2.26 W/cm2, with (sham) or without (verum) interposition of Sorbothane film
Study NCT05697172 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low-intensity focused ultrasound
Description: 80-second stimulus with an estimated tissue ISSPA=2.26 W/cm2, with (sham) or without (verum) interposition of Sorbothane film
Study NCT06273319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OXYGEN THERAPY
Description: 15 AND 30 LT OXYGEN TREATMENT
Study NCT06547593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multifaceted nutrition intervention
Description: In this group, a 3-month multifaceted nutrition intervention will be conducted. The specific content is as follows:~1. Anti-inflammatory dietary management: the elderly will receive an anti-inflammatory dietary menu designed based on the Chinese Dietary Guidelines for the Elderly (2022 Edition) provided by researchers.~2. Personalized nutritional intervention management: WeChat groups will be established to record the dietary status of the research subjects. The research subjects will be asked to keep a dietary diary and take photos of their diet daily. Trained researchers will record their daily diet and provide timely feedback to the research subjects.~3. Health education: Nutrition and health knowledge lecture will be held for elderly family caregivers and the elderly themselves every two weeks. The content will include basic knowledge of frailty, prevention and treatment guidance, health outcomes, medication management, and healthy behaviors.
Study NCT06547593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional and Exercise Combined Intervention
Description: To investigate the combined effects of nutrition and exercise, this group added exercise intervention in addition to the corresponding intervention measures of the nutrition intervention group. The subjects were required to exercise 3 times a week, 1 hour each time. The project included 10 minutes of warm-up exercises (stretching), 10-20 minutes of aerobic exercise (balance ability, leg and core muscle strength, etc.), 10-20 minutes of muscle resistance strength training (legs, buttocks, feet, upper limbs, etc.) and 10 minutes of relaxation training. All exercise programs were uniformly trained by professional coaches, and compliance was ensured by uploading photos to punch the clock. The intervention period is 3 months, with a follow-up of 9 months.
Study NCT06547593 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The control group will undergo routine community health management, including regular chronic disease health education lectures, provision of health education materials, health counseling services, and comprehensive health examinations by qualified medical professionals.
Study NCT05140642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated annotation of the left ventricle through deep learning
Description: A semantic segmentation deep learning model will identify the left ventricle and label the left ventricle. The AI model will produce an assessment of LVEF using video based features.
Study NCT05140642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sonographer Measurement of LVEF
Description: Standard practice sonographer measurement of left ventricle and assessment of LVEF
Study NCT06273319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OXYGEN THERAPY
Description: 15 AND 30 LT OXYGEN TREATMENT
Study NCT05967013 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Injections in thigh of 0.625 mL of physiological serum with ZENEO® injector, on bare skin and through clothing.
Description: All injections with ZENEO® injector will be performed in the thigh. Due to MRI performance constraints, injection sites will be identified on the same thigh/leg at each treatment period: first leg on treatment period 1, opposite leg on treatment period 2.~At each treatment period, two injection sites will be identified spaced 8 to 15 cm apart. The 2 injections should be performed on the same leg at each treatment period.~In total, 2 injections will be performed per treatment period, and subjects will receive 4 injections during the study :~* 2 injections on bare skin: 1 with GAMMA configuration of ZENEO® injector \& 1 with GAMMA-Low configuration ZENEO® injector.~* 2 injections through clothing: 1 with GAMMA configuration of ZENEO® injector \& 1 with GAMMA-Low configuration ZENEO® injector.
Study NCT04762680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1
Description: Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Study NCT04762680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2
Description: Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Study NCT04762680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3
Description: Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Study NCT04565145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kava Dietary Supplement
Description: Participants will be given three 75mg kava capsules per day for one week
Study NCT04565145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be given three placebo capsules per day for one week
Study NCT06371235 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pregiferon
Description: This Study aims to study the transmission of anti-interferon alpha autoantibodies from mother to child viaplacental barrier
Study NCT04528667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-5656
Description: STI-5656 (abivertinib maleate) is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor.
Study NCT04528667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT06255119 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D Therapy Thrive
Description: A novel virtual reality software intervention that utilizes elements of Cognitive Behavioral Therapy to improve outcomes for inpatients with OUD.
Study NCT05448274 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will consist of solely glycerol-phosphate-buffered isotonic saline.
Study NCT05448274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ruminococcus torques
Description: 10\^11 live bacterial cells in glycerol-phosphate-buffered isotonic saline
Study NCT05340088 — intervention group
Intervention type: PROCEDURE
Intervention: Retrograde intrarenal surgery after DJ stent placement
Description: Patients who underwent RIRC for 2-4 weeks after DJ stent placement for passive dilatation
Study NCT00111605 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 gag DNA
Description: A 0.75 mL intramuscular injection of HIV gag DNA vaccine into the deltoid
Study NCT00111605 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 gag DNA plus IL-12 DNA adjuvant
Description: Injection IL-12 DNA adjuvant intramuscularly into the deltoid
Study NCT00111605 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine)
Description: A 1 mL intramuscular injection in the deltoid
Study NCT00111605 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium chloride injection (0.9%)
Description: All placebo groups will receive an intramuscular injection of sodium chloride (0.9%) in the deltoid.~Group 1 will receive a 0.75 mL injection on Days 0, 28, and 84. Group 2 will receive a 0.8 mL injection on Days 0, 28, and 84. Group 3 will receive a 1.0 mL injection on Days 0, 28, and 84. Group 4 will receive a 1.5 mL injection on Days 0, 28, and 84. Group 5 will receive a 0.75 mL injection on Days 0, 28, 84, 168, and 273. Group 6 will receive a 1.5 mL injection on Days 0, 28, 84, 168, and 273. Group 7 will receive a 1.5 mL injection on Days 0, 28, and 84 and a 1 mL injection into the deltoid on Days 168 and 273.
Study NCT04762680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A
Description: Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Study NCT06061120 — intervention group
Intervention type: DEVICE
Intervention: Recording of an extended high-resolution ECG
Description: Recording of an extended high-resolution ECG
Study NCT05435729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-9632P 27.5 mg
Description: Single dose of DSP-9632P 27.5 mg
Study NCT05435729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-9632P 82.5 mg
Description: Single dose of DSP-9632P 82.5 mg
Study NCT05435729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for DSP-9632P
Study NCT05435729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-9632P 55.0 mg
Description: Multiple dose of DSP-9632P 55.0 mg
Study NCT05435729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa formulation
Description: Single dose of Levodopa formulation
Study NCT05184205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Photodisinfection
Description: The procedure is initiated by swabbing the Formulation Applicator, pre-saturated with photosensitizer formulation, inside the patient's nares. The operator then connects the Nasal Light Illuminator (NLI) to the Light Source and inserts the NLIs into the patient's nostrils. The Light Source is turned on, and a 4-minute illumination cycle provides two channels of diffused red light (one for each nostril) to activate the applied formulation. Illumination stops automatically upon completion of the 4-minute cycle. The process is then repeated using two new Formulation Applicators to ensure full disinfection coverage.
Study NCT05184205 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Control
Description: Patients who are SARS-CoV-2 positive whose PCR levels are followed but no active intervention will be done. Saline will be used in their nose and the light device will be inserted but not turned on. Patient will be wearing light protecting glasses.
Study NCT04398238 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: evaluation by transfusion medicine specialist
Description: screening for anemia causes and treatment: iron/folate/vitamin B12 supplementation, Erythropoietin administration if indicated
Study NCT04939987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Opioid Control Cohort (One treatment selected)
Study NCT04939987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Experimental Cohort (Multimodal Approach)
Study NCT04939987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone-Acetaminophen
Description: Opioid Control Cohort (One treatment selected)
Study NCT04939987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone-Acetaminophen
Description: Opioid Control Cohort (One treatment selected)
Study NCT04939987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Experimental Cohort (Multimodal Approach)
Study NCT04939987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Experimental Cohort (Multimodal Approach)
Study NCT04762680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03
Description: Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Study NCT04762680 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B
Description: Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Study NCT04762680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1
Description: Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Study NCT04762680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2
Description: Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Study NCT04762680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3
Description: Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Study NCT04762680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4
Description: Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Study NCT04762680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03
Description: Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Study NCT06204627 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TDCS
Description: Technique of non-invasive brain stimulation by direct current (TDCS) which involves the modulation of excitability and brain activity, capable of promoting reorganization of the cortical representation of the body schema or motor planning, and consequently, pain relief.
Study NCT04939987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: Experimental Cohort (Multimodal Approach)
Study NCT04939987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Experimental Cohort (Multimodal Approach)
Study NCT06409754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation Therapy coupled to a P-300 based Brain-Computer Interface
Description: The intervention involves a BCI control strategy based on a modified version of the classic P300 Donchin Speller Interface, where the matrix of letters and symbols is replaced by a set of pictures including five hand gestures and wrist orientations: hand opening, grasping, pinching, pronation, and supination. This BCI approach is based on the oddball paradigm, relying on conscious recognition by the user of the intensification of a particular target movement picture, within a sequence of other, non-target, random visual stimuli. This process should evoke the P300 component in the event related potential. The aim of the training sessions is to link an action observation/target selection task, mediated by the P300-based BCI, with the practice of a FES-assisted functional task involving the target movement picture selected. Users will be instructed to synchronize their voluntary movements with the ones induced by FES, to achieve the functional target goal.
Study NCT06409754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical and Occupational Therapy
Description: Conventional physical and occupational therapy will include sessions of joint mobility, muscle strength, task-specific training, sensitivity reeducation and coordination exercises directed by an experienced professional therapist.
Study NCT06409754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical and Occupational Therapy
Description: Conventional physical and occupational therapy will include sessions of joint mobility, muscle strength, task-specific training, sensitivity reeducation and coordination exercises directed by an experienced professional therapist.
Study NCT06204627 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Recognize (hand) - Laterality
Description: This technique stimulates the ability to recognize hand images as right/left quicklPatients with chronic pain present delayed recognition of hand laterality, which is related to the duration of symptoms and the pain evoked by the execution of the movement. Thus, this technique can have beneficial effects in breaking the pain.
Study NCT04969406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brillouin Spectroscopy via BOSS System
Description: Biomechanical Imaging of the Cornea and Lens
Study NCT05013320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate + dexmedetomidine
Description: Intravenous glycopyrrolate before anesthetic induction. Dexmedetomidine administration during the surgery.
Study NCT05013320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine administration during the surgery.
Study NCT04943146 — intervention group
Intervention type: DRUG
Intervention: Prednisone 10 MG+aspirin 100MG
Description: Discontinue medication based on early pregnancy outcome
Study NCT05345392 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Intervention (MBI)
Description: The mindfulness-based intervention is based on mindfulness-based stress reduction and mindfulness-based cognitive therapy, borrowing publicly available materials from the Mindfulness in Schools Program and Acceptance and Commitment Therapy. The MBI consists of 8 weekly groups, 45-60 minutes in length, and include 3-8 youth.
Study NCT05345392 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Wellness Intervention (HWI)
Description: The control intervention is inspired by the Health Enhancement Program that has been adapted for youth 11-14 years old, using brief, engaging, and age-appropriate activities to address topics related to physical and mental health. HWI consists of 8 weekly groups, 45-60 minutes in length, and include 3-8 youth.
Study NCT05858788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441566
Description: Tablet
Study NCT05390333 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-Care Sampler for Family Carer Partners
Description: The 6-week Self-Care Sampler for Family Caregivers program was created to provide a variety of evidence-based self-care practices that improve the mental and physical health of caregivers by relieving stress. Sessions will take place once a week for 90 minutes, each starting with a centering exercise and focusing on a new form of self-care. The first 30 minutes will be used for a support group and the last 60 minutes will be for a self-care practice. Self-care practices that will be offered throughout the 6 weeks include mindfulness, mindful drawing, exercise, and health prevention and promotion.